Biotech entity

Indian Pharmaceutical Alliance (IPA)

Company

Every one of those 1 sits in a single category, pharma. Indian Pharmaceutical Alliance (IPA) is most often covered alongside Donald Trump, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.

Last mentioned: Aug 1, 2026

Entity pulse

Recent coverage · Indian Pharmaceutical Alliance (IPA)

1 story
6 avg impact
0% positive
100% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.

  • 100% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Indian Pharmaceutical Alliance (IPA)

Every one of those 1 sits in a single category, pharma. Indian Pharmaceutical Alliance (IPA) is most often covered alongside Donald Trump, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. Their average consequence score of 6 runs above the beat's 5.7 for that window. We currently track 1 Biotech story that mention Indian Pharmaceutical Alliance (IPA), all published on August 1, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Indian Pharmaceutical Alliance (IPA). Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Indian Pharmaceutical Alliance (IPA) 1

Pharma Negative

200% US Tariff Threatens Indian Pharma's $50B+ US Generic Business

The proposed US tariff on generic drugs—jumping to 200%—poses an existential threat to Indian pharmaceutical companies that have long dominated the American market. With margins razor-thin and a 4-5 year timeline needed to onshore production, industry leaders call the plan 'completely out of scope,' potentially forcing a major restructuring of global generic supply chains.

2 sources

Source: heraldglobe.com · milwaukeesun.com

Indian Pharmaceutical Alliance (IPA) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.